Status:
COMPLETED
Validation of the Stockholm3 Test for Detection of Prostate Cancer in the Swiss Population
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Department of Urology, University Hospital Freiburg, Freiburg, Germany
Department of Urology, Kantonsspital Graubünden, Chur, Switzerland
Conditions:
Prostate Cancer
Localized Carcinoma
Eligibility:
MALE
18-99 years
Brief Summary
The purpose of this study is to collect blood samples to investigate the prognostic performance of the STHLM3 test in a population of Swiss and German men suspected of harbouring prostate cancer based...
Eligibility Criteria
Inclusion
- Planned prostate biopsy due to suspicion of prostate cancer (usually due to a combination of elevated PSA levels \[e.g. \>2.5 ng/ml\] and/or pathological digital rectal examination and/or MRI-findings)
- Written informed consent by the participant
Exclusion
- Severe anemia (Hb \<60g/l)
- Previously already established diagnosis of prostate cancer.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
380 Patients enrolled
Trial Details
Trial ID
NCT05294627
Start Date
January 1 2020
End Date
October 1 2023
Last Update
December 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Urology
Basel, Switzerland, 4031